Dinoprost-13C5

Dinoprost-13C5 is 13C labeled Dinoprost (HY-12956) . Dinoprost (Prostaglandin F2α) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL) . Dinoprost plays a key role in the onset and progression of labour[1][2].

Product Specifications

Product Name Alternative

Prostaglandin F2α-13C5; PGF2α-13C5

UNSPSC

12352211

Target

Apoptosis; Autophagy; Endogenous Metabolite; Isotope-Labeled Compounds; Prostaglandin Receptor

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Autophagy; GPCR/G Protein; Metabolic Enzyme/Protease; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/dinoprost-13c5.html

Solubility

10 mM in DMSO

Smiles

CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=[13C]\[13C][13C][13C][13C](O)=O)[C@@H](O)C[C@H]1O

Molecular Formula

C15 13C5H27O5

Molecular Weight

352.39

References & Citations

[1]Hagen Thieme, et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006 Mar;47 (3) :938-45.|[2]Xin Wen, et al. Prostaglandin F2α Induces Goat Corpus Luteum Regression via Endoplasmic Reticulum Stress and Autophagy. Front Physiol. 2020 Sep 11;11:868.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.